Program directory · National Research Council Canada
Biologics Manufacturing Centre
- Department
- National Research Council Canada
- Program code
- BNQ26 (NRC)
- Core responsibility
- Science and Innovation
- In Departmental Plans
- 2023-24 – 2026-27 · New since an earlier plan
What it does
The Biologics Manufacturing Centre (BMC) is an end-to-end Good Manufacturing Practices (GMP) biomanufacturing facility located at the NRC Royalmount campus. The BMC is self-contained and is managed and operated by a not-for-profit (NFP) entity to fulfill its public good mandate. The NRC leases the facility to this organization and provides $17 million per year through a contribution agreement to offset facility operational costs. While the BMC outputs and outcomes are not directly under control of the NRC, its performance is monitored to ensure effective stewardship of Government funds.
The BMC was built by the NRC to provide Canada with a domestic vaccine production capacity, and the ability to produce, especially in times of need in the supply chain. In non-pandemic periods, the BMC provides domestic capacity to undertake public interest projects, such as the production of orphan drugs for rare diseases, to support improved health outcomes for Canadians and protect those at high risk. The BMC may also provide domestic biomanufacturing GMP production for universities and SMEs, to contribute to the sector’s growth, knowledge and capacity.
Given the NFP arrangement that is being put in place, the long-term role of the NRC will be to provide effective oversight of the contribution agreement between the BMC and the NRC and to see that the objectives of the BMC are being realized.
Source: the department's Program Inventory, via GC InfoBase.
History and lineage
First appears in GC InfoBase's actual spending by program in 2023-24. The data does not record when a program was created; it may be older than its first appearance here, which is limited by the sources (program spending starts in 2010-11, Departmental Plans in 2018-19).
| Program | Relation | Years with data | Actual spending over those years |
|---|---|---|---|
| Biologics Manufacturing Centre | This program | 2023-24 – 2028-29 | $48.5M |
No earlier or later program in the same department has a similar name.
Significant changes in scope and budget
Detected from the data: renames between plans, programs it appears to replace, merge with or split into (matched by name), year-over-year changes in spending of at least 25% and $5M, or in employees of at least 20% and 25 FTEs, linked budget measures, and results indicators added or dropped.
| Year | What changed | Source |
|---|---|---|
| 2024-25 | Spending $27.3M, against $21.2M in 2023-24 (+29%). | Actual spending (GC InfoBase) |
| 2025-26 | Indicators added: Percentage of time that the BMC facility is operational | Departmental Results Framework (GC InfoBase) |
| 2025-26 | Indicators dropped: Composite score of BMC objectives and obligations met by the not-for-profit | Departmental Results Framework (GC InfoBase) |
| 2025-26 | Planned spending $38.2M, against $27.3M in 2024-25 (+40%). | Latest Departmental Plan |
| 2026-27 | Planned spending $21M, against $38.2M in 2025-26 (−45%). | Latest Departmental Plan |
Success criteria
The program's indicators from its department's Departmental Results Framework: the target set in each year's plan, and the result reported the following year. Source: GC InfoBase.
Historical: targets against results
Bars: result reported. Dashed line: target.
| Report year | Target | Due | Result | Status |
|---|---|---|---|---|
| 2023-24 | ≥ 80% | 2024 | 97.5% | Met |
| 2024-25 | ≥ 80% | 2025 | 86% | Met |
Current: the 2026-27 plan's targets
Bars: result reported. Dashed line: target.
| Report year | Target | Due | Result | Status |
|---|---|---|---|---|
| 2026-27 | ≥ 97% | 2027 | — | Planned |
Future goals: targets due after 2026-27
No targets with a later due date.
Spending and employees: planned against actual
Spending
Show the numbers
| Fiscal year | Planned | Actual |
|---|---|---|
| 2023-24 | $19.6M | $21.2M |
| 2024-25 | $20M | $27.3M |
| 2025-26 | $38.2M | — |
| 2026-27 | $21M | — |
| 2027-28 | $21M* | — |
| 2028-29 | $18.7M* | — |
Employees (FTEs)
Show the numbers
| Fiscal year | Planned | Actual |
|---|---|---|
| 2023-24 | 0 | 0 |
| 2024-25 | 0 | 0 |
| 2025-26 | 0 | — |
| 2026-27 | 0 | — |
| 2027-28 | 0* | — |
| 2028-29 | 0* | — |
Planned spending, plan by plan
Each row is one year's Departmental Plan and its forecast for the next three fiscal years; read a column down to see how the forecast for one year changed. The last row is what was actually spent. Click an amount for its source. Biggest changes in federal spending plans
| Plan | 2023-24 | 2024-25 | 2025-26 | 2026-27 | 2027-28 | 2028-29 |
|---|---|---|---|---|---|---|
| 2023-24 plan | $19,592,539 | $20,000,000 | $20,000,000 | |||
| 2024-25 plan | $20,000,000 | $20,000,000 | $20,000,000 | |||
| 2025-26 plan | $38,186,564 | $20,193,829 | $20,193,057 | |||
| 2026-27 plan | $20,987,674 | $20,986,902 | $18,693,142 | |||
| Actual | $21,177,533 | $27,321,324 |
Actual spending is from Departmental Results Reports and the Public Accounts, as published in GC InfoBase. FTEs are full-time equivalents.